Welcome to our dedicated page for Armata Pharmaceuticals news (Ticker: ARMP), a resource for investors and traders seeking the latest updates and insights on Armata Pharmaceuticals stock.
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to address antibiotic-resistant and challenging bacterial infections. Utilizing proprietary bacteriophage-based technology, Armata is advancing a broad pipeline of both natural and synthetic phage candidates targeting critical pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus.
Armata's innovative approach includes developing clinical candidates like AP-PA02 and AP-SA02. AP-PA02, a five-phage cocktail, is aimed at treating Pseudomonas aeruginosa infections, particularly in people with cystic fibrosis. The company is currently analyzing data from its SWARM-P.a. study to progress into a Phase 2b/3 registrational study in 2024. Meanwhile, AP-SA02, designed to combat Staphylococcus aureus bacteremia, has shown positive results in Phase 1b trials and is moving into Phase 2a with support from the U.S. Department of Defense.
In collaboration with Merck, Armata is developing proprietary synthetic phage candidates to address other significant infectious diseases. The company’s commitment to innovation extends to its in-house phage-specific GMP manufacturing capabilities, ensuring high-quality production from bench to clinic.
Financially, Armata reported grant revenue of $1.0 million for the second quarter of 2023, attributed to its AP-SA02 program. The company's research and development expenses were approximately $8.3 million, reflecting ongoing investments in clinical trials and personnel. As of June 30, 2023, Armata held $12.5 million in unrestricted cash and cash equivalents, with a subsequent $25 million credit agreement with Innoviva bolstering its financial position.
Recent updates include the initiation of the Phase 2a portion of the diSArm study for AP-SA02 and the positive topline data from the SWARM-P.a. clinical trial. Armata is poised for significant advancements, supported by its strategic partnerships and robust development pipeline.
Armata Pharmaceuticals (ARMP) has completed enrollment for its Phase 2 Tailwind study of inhaled AP-PA02 in non-cystic fibrosis bronchiectasis (NCFB) patients with chronic pulmonary Pseudomonas aeruginosa infection. The study, which follows the successful SWARM-P.a. trial in cystic fibrosis patients, evaluates the safety, tolerability, and efficacy of AP-PA02. Topline results are expected in the second half of 2024, with plans to commence a pivotal Phase 3 trial in 2025. The study includes two cohorts: one receiving phage-only therapy and another receiving a combination with inhaled antibiotics. The final follow-up visit is scheduled for August 7, 2024.
Armata Pharmaceuticals (NYSE American: ARMP), a clinical-stage biotech company, will present at the Viruses of Microbes 2024 conference in Cairns, Australia. The event occurs from July 15-19, 2024. Steven Branston, the Australia Site Head, will deliver a presentation titled 'Advancing Bacteriophage Therapy from Discovery to Clinical Trials' on July 18 at the Phage Therapy Session 2 – Clinical Application. The presentation will cover the progress in bacteriophage therapy, a promising approach for treating antibiotic-resistant bacterial infections.
Armata Pharmaceuticals, Inc. released its First Quarter 2024 financial results and corporate update. The company secured a $35 million credit agreement, continued clinical trials for phage therapeutics, and advanced its biologics manufacturing facility. Dr. Deborah Birx, CEO, highlighted progress in developing treatments for bacterial infections, with positive enrollment in clinical studies. The financials showed a grant revenue of $1.0 million, reduced research and development expenses, increased general and administrative expenses, resulting in a loss of $10.2 million from operations. Armata held $37.9 million in cash as of March 31, 2024.
FAQ
What is the current stock price of Armata Pharmaceuticals (ARMP)?
What is the market cap of Armata Pharmaceuticals (ARMP)?
What does Armata Pharmaceuticals specialize in?
What are Armata's lead clinical candidates?
Who are Armata's key collaborators?
What are the recent financial highlights for Armata?
What recent developments have been announced by Armata?
In which clinical stage is Armata's AP-PA02 candidate?
What is the significance of Armata's in-house GMP manufacturing?
How does Armata plan to address antibiotic-resistant infections?
What is the role of Merck in Armata's development programs?
What grants and financial support has Armata received?
